# A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

Study · id `cardio:ct-nct07404553` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07404553](<https://clinicaltrials.gov/study/NCT07404553>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07404553

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 126 participants.

## Technical summary

Registry record NCT07404553. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-30 (actual); primary completion 2028-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2/3
- Enrolled: 126 participants (planned count; ClinicalTrials.gov record NCT07404553, source copy `cardio:ctgov-nct07404553-2026-06-16`, retrieved 2026-10-31)
- Started: 2026-04-30 (actual) (ClinicalTrials.gov record NCT07404553, source copy `cardio:ctgov-nct07404553-2026-06-16`, retrieved 2026-10-31)
- Primary completion: 2028-07 (anticipated) (ClinicalTrials.gov record NCT07404553, source copy `cardio:ctgov-nct07404553-2026-06-16`, retrieved 2026-10-31)
- Completion: 2028-08 (anticipated) (ClinicalTrials.gov record NCT07404553, source copy `cardio:ctgov-nct07404553-2026-06-16`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07404553, source copy `cardio:ctgov-nct07404553-2026-06-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07404553-2026-06-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors
- Condition: Hypercholesterolemia
- Intervention (Drug): SHR-1918 Injection
- Intervention (Drug): SHR-1918 Injection Placebo
- Lead sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd (`cardio:org-beijing-suncadia-pharmaceuticals-co-ltd`)

## Provenance

Content hash: de0b0e1428cf34fa42ca42384e5da7c8694976561634ab9c513d0f6740df8317
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
